))
Most Patients with BRAF-mutant Metastatic Melanoma Benefit from First-line Immunotherapy
Manage episode 407462020 series 3560609
Content provided by Jacqueline Stone and OBR Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jacqueline Stone and OBR Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Michael B. Atkins, MD, talks with Robert A. Figlin, MD, about the importance of sequencing therapies for patients with BRAF-positive metastatic melanoma. Data from the DREAMSeq trial, which Dr Atkins updated at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, show a significant survival advantage at two years for patients who receive ipilimumab plus nivolumab prior to receiving a BRAF/MEK inhibitor. But not all patients fit that paradigm. Listen as Dr Atkins shares which patients he starts on immunotherapy and when he thinks is the best time for crossover to a targeted agent.
111 episodes
Share
